Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "EU"

4932 News Found

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
News | September 16, 2025

Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke


Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav
News | September 16, 2025

Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav

The inspection was carried out between May 26, 2025 and May 31, 2025


Briefs: Alembic Pharmaceuticals and Tyche Industries
Drug Approval | September 14, 2025

Briefs: Alembic Pharmaceuticals and Tyche Industries

Alembic receives EIR from USFDA for facility at Panelav


iRegene Therapeutics secures series B+ financing
Biotech | September 12, 2025

iRegene Therapeutics secures series B+ financing

NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation


Shukra Pharmaceuticals inks distribution tie-up with Wockhardt
Supply Chain | September 12, 2025

Shukra Pharmaceuticals inks distribution tie-up with Wockhardt

The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)


Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries
News | September 12, 2025

Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries

Hemant Surgical Industries receives order


MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline
News | September 09, 2025

MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline

Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval


Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease
Diagnostic Center | September 05, 2025

Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease

RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options


Brenntag Specialties selected European distributor for Kerry’s pharmaceutical-grade acetates
Supply Chain | September 04, 2025

Brenntag Specialties selected European distributor for Kerry’s pharmaceutical-grade acetates

Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates